Selected Publications

Verbeke R, Lore K, Hogan MJ, Pardi N.* * corresponding author : Innate immune mechanisms of mRNA vaccines Immunity Nov 2022.

McMahon M, O'Dell G, Tan J, Sárközy A, Vadovics M, Carreño JM, Puente-Massaguer E, Muramatsu H, Bajusz C, Rijnink W, Beattie M, Tam YK, Kirkpatrick Roubidoux E, Francisco I, Strohmeier S, Kanekiyo M, Graham BS, Krammer F, Pardi N.* * corresponding author : Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc Natl Acad Sci U S A Nov 2022.

Carreño JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, Desai P, Aberg JA, Miller RL, Study Group P, Pardi N, Simon V, Krammer F.: mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine Oct 2022.

Li D, Martinez DR, Schäfer A, Chen H, Barr M, Sutherland LL, Lee E, Parks R, Mielke D, Edwards W, Newman A, Bock KW, Minai M, Nagata BM, Gagne M, Douek DC, DeMarco CT, Denny TN, Oguin TH 3rd, Brown A, Rountree W, Wang Y, Mansouri K, Edwards RJ, Ferrari G, Sempowski GD, Eaton A, Tang J, Cain DW, Santra S, Pardi N, Weissman D, Tomai MA, Fox CB, Moore IN, Andersen H, Lewis MG, Golding H, Seder R, Khurana S, Baric RS, Montefiori DC, Saunders KO, Haynes BF.: Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. Nat Commun Oct 2022.

Jitthamstaporn S, Inthong R, Audomsun D, Chanasit S, Thanasarnthungcharoen C, Lin PJC, Weissman D, Pardi N, Jacquet A.: Nucleoside-modified mRNA vaccines yield robust blocking antibody responses against major house dust mite allergens. Allergy Sept 2022.

Wisitrasameewong W, Champaiboon C, Surisaeng T, Sa-Ard-Iam N, Freire M, Pardi N, Pichyangkul S, Mahanonda R.: The Impact of mRNA Technology in Regenerative Therapy: Lessons for Oral Tissue Regeneration. J Dent Res Aug 2022.

Pardi N*, Carreño JM, O'Dell G, Tan J, Bajusz C, Muramatsu H, Rijnink W, Strohmeier S, Loganathan M, Bielak D, Sung MMH, Tam YK, Krammer F, McMahon M. * corresponding author : Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses Nat Commun Aug 2022.

Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N.* * corresponding author : Lyophilization provides long-term stability for a lipid nanoparticle-formulated nucleoside-modified mRNA vaccine. Mol Ther May 2022.

Parhiz H, Brenner JS, Patel P, Papp TE, Shahnawaz H, Li Q, Shi R, Zamora M, Yadegari A, Marcos-Contreras OA, Natesan A, Pardi N, Shuvaev VV, Kiseleva R, Myerson J, Uhler T, Riley RS, Han X, Mitchell MJ, Lam K, Heyes J, Weissman D, Muzykantov V.: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE). J Control Release April 2022.

Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Eaton A, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Korber B, Wagh K, Tam Y, Barbosa C, Alam SM, Williams WB, Tian M, Alt FW, Pardi N, Weissman D, Haynes BF.: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Rep Mar 2022.